Background/Aim: For intermediate risk acute myeloid leukemia patients, allogeneic
hematopoietic stem cell transplantation (alloSCT) and chemotherapy are equally …

Aims Allogeneic stem cell transplantation (alloSCT) in first complete remission (CR1) has
become a standard of care for many patients (pts) with intermediate or high risk acute …

Hematopoietic stem cell transplantation (HSCT) and consolidation chemotherapy have been
used to treat intermediate-risk acute myeloid leukemia (AML) patients in first complete …

Acute myeloid leukemia (AML) is a very heterogeneous disease. Prognosis is related not
only to intrinsic characteristics such as cytogenetics and molecular markers, but also the …

Importance The ideal postremission strategy in intermediate-risk acute myeloid leukemia
(AML) in first complete remission (CR) has been a matter of debate. Objective To explore the …

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the main therapeutic
option for most patients with high risk acute myeloid leukemia (AML). In order to determine …

Introduction Despite substantial progress in the treatment of newly diagnosed AML, 20% to
40% of patients do not achieve remission with conventional induction chemotherapy. In …

In acute leukemia, advances have been made in therapeutic strategies centered on
allogeneic hematopoietic stem cell transplantation (allo-SCT), three of which are presented …

In 2014, autologous hematopoietic cell transplant (autoHCT) was removed from the National
Comprehensive Cancer Network guidelines as a recommended treatment for patients with …

Background: Allogeneic hematopoietic stem-cell transplantation (ahsct) is associated with
significant morbidity and mortality, but it can cure carefully selected patients with acute …